Applied Therapeutics Inc (APLT) Return on Equity ROE from the third quarter 2025 to third quarter 2024 and annually, average high and low, overall ranking from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Applied Therapeutics Inc   (NASDAQ: APLT)

Applied Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Applied Therapeutics Inc in the third quarter 2025?
Applied Therapeutics Inc recorded a cumulative net loss of $-18 million during 12 months ending in the third quarter 2025, resulting in a negative return on equity (ROE) of -65.63%.

Within the Major Pharmaceutical Preparations industry 179 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 2792, from total ROE ranking in the second quarter 2025 at 3021.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Equity Change - -75.91 % -45.51 % - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -18 -68 -44 -106 -187
Return On Equity (TTM) -65.63 % -231.58 % -101.21 % -208.55 % -583.37 %
APLT's Total Ranking # 2792 # 3021 # 3217 # 3634 # 3667
Equity (TTM) in Millions -1 17 37 57 6
Seq. Equity Change - -52.44 % -35.68 % 867.52 % -91.86 %
Seq. Net Income Change - - - - -

Back to APLT Management Effectiveness >> APLT's 5 Years Annual ROE >> Compare APLT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 180
Sector # 414
Overall # 2792

Return On Equity Statistics
High Average Low
-46.28 %
-595.46 %
-5544.59 %
(Jun 30 2020)   (Jun 30 2023)



  News about Applied Therapeutics Inc Return on Equity ROE

Navigating Quality Challenges: Applied Therapeutics Appoints Industry Veteran Amid Significant Financial Losses

In a strategic move aimed at bolstering its operational integrity, Applied Therapeutics Inc. has appointed Reena Thomas Colacot as Vice President and Head of Quality. Ms. Colacot arrives with over 25 years of quality leadership experience across the biopharmaceutical and medical device sectors, insights that are particularly crucial in light of the company s current financial landscape.Applied Therapeutics, a biotechnology firm focused on the development of novel treatments for critical illnesses, recently reported a cumulative net loss of $187 million during the 12 months ending in the third quarter of 2024. This substantial financial setback has translated into an alarming negative return on equity (ROE) of -583.37%, raising serious questions about the efficiency and sustainability of its operations.

Leadership Shift Amid Financial Turmoil: Applied Therapeutics Faces Investor Scrutiny and Legal Battles

In an unexpected turn of events, Applied Therapeutics, Inc. has appointed John H. Johnson as Executive Chairman, a move that coincides with the departure of Shoshana Shendelman as CEO and the appointment of Les Funtleyder as interim Chief Executive Officer. This leadership reshuffling comes at a turbulent time for the biotech company, which has recently faced mounting financial challenges and legal scrutiny that may threaten its future.As of the third quarter of 2024, Applied Therapeutics recorded a staggering cumulative net loss of $187 million, translating to a negative return on equity (ROE) of -583.37%. This dismal financial performance places the company in a precarious position within the Major Pharmaceutical Preparations industry, where 303 other companies managed to achieve a higher ROE. Despite this, Applied Therapeutics reported an improved ROE ranking, moving from 3667 in the second quarter of 2024 to 3070. This modest climb, however, is overshadowed by the serious implications of its financial losses and the recent legal troubles it now faces.



APLT Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 57 -17 4 63 82
Y / Y Equity Change - - -93.51 % -23.68 % 151.29 %
Net Income in Millions -106 -120 -83 -106 -94
Y / Y Net Income Change - - - - -
Return On Equity -185.29 % - -2031.72 % -168.83 % -114.67 %

Back to APLT Management Effectiveness >> APLT's 5 Years Annual ROE >> Compare APLT ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
APLT's' Return on Equity at Yahoo Finance
APLT's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for APLT's Competitors
Subscribers only: Roe for Applied Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for APLT's Customers




Companies with similar Return On Equity at Sep 30 2025, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.